Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.54 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844740 | 0.92 | KDM4E (0.67) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL23552408 | 0.89 | KDM4E (0.81) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30581237 | 0.85 | KDM4E (0.66) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29076183 | 0.85 | KDM4E (0.66) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30581236 | 0.84 | KDM4E (0.60) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30581249 | 0.84 | KDM4E (0.60) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29076126 | 0.84 | KDM4E (0.60) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29076186 | 0.84 | KDM4E (0.60) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29076118 | 0.81 | KDM4E (0.70) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30581245 | 0.81 | KDM4E (0.70) | KDM4ENPSR1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689928-B2 | PREPARED IN SITU FROM A NICKEL, PALLADIUM OR PLATIINUM COMPOUND AND A NITROGEN-CONTAINING LIGAND; OLIGOMERIZING OLEFIN MONOMERS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2004-02-10 | — | — | US | claimed |
| WO-2003027130-A2 | TRANSITION METAL COMPLEXES FOR PREPARING OLEFIN OLIGOMERS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2003-04-03 | — | — | WO | claimed |
| US-20020045790-A1 | Transition metal complexes and oligomers therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-18 | — | — | US | claimed |
| EP-1492746-A1 | SELECTIVE COUPLING OF TERMINAL OLEFINS WITH ETHYLENE TO MANUFACTURE LINEAR ALPHA-OLEFINS | ExxonMobil Research and Engineering Company (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003072529-A1 | SELECTIVE COUPLING OF TERMINAL OLEFINS WITH ETHYLENE TO MANUFACTURE LINEAR ALPHA-OLEFINS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045790-A1 | Transition metal complexes and oligomers therefrom | NCF1, ICOSLG, NPM1 | KDM4E 4701/4885NPSR1 1935/4885ALDH1A1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.